|
|
Article: Further Evidence of Valdoxan[R] Superior Antidepressant Efficacy in Depressed Patients.
- Article from:
- Biotech Week
- Article date:
- September 30, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Further evidence of the superior antidepressant efficacy of Valdoxan[R]/Thymanax[R] (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided by Servier. The new data demonstrates superior antidepressant efficacy over the SSRI fluoxetine, in severely depressed patients.(1)
This new data, in addition to the results of the international development programme in over 6,000 patients and ...